Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - raloxifene hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - drospirenone, quantity: 4 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; triacetin; polysorbate 80; titanium dioxide; indigo carmine aluminium lake; iron oxide yellow - contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: hypromellose; lactose monohydrate; magnesium stearate; maize starch; macrogol 6000 - estro-pess is indicated for the treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women.,estro-pess is not intended for children or males.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - estradiol hemihydrate, quantity: 1 mg; progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: mono- and di- glycerides; gelatin; glycerol; purified water; lauroyl macrogolglycerides; hydrolysed gelatin; allura red ac; titanium dioxide; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; polyvinyl acetate phthalate; macrogol 400 - bijuva 1/100 is indicated for use during continuous combined hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and with at least 12 months since last menses.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - adrenaline (epinephrine) acid tartrate, quantity: 4.5 microgram/ml (equivalent: adrenaline (epinephrine), qty 2.5 microgram/ml); bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: sodium metabisulfite; hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia; epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia; continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - English - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - cyanocobalamin,ferrous fumarate,folic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; dilute hydrochloric acid - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; dilute hydrochloric acid - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.